Medicines Authority Logo
  • SiteMap
  • Careers
Decrease Font Size Reset Font Size Increase Font Size
  • Home

  • Organisation

    • About Us
      • Mission and Objectives
      • Directorates and Units
      • Committees and Working Groups
      • Annual Reports
      • Heads of Medicines Agencies
      • Working at the Medicines Authority
      • Career Opportunities
      • Bank and Payment Details
    • Data and Information
      • Freedom of Information
      • Data Protection
      • Presentations and Publications
    • Links
      • Pharmacy Roster
      • eHealth
      • Government of Malta
      • Heads of Medicines Agency
      • Innovative Medicines Initiative
      • European Medicines Agency
    • Home
  • Legislation

    • Introduction
      • Better Regulation
    • Legislation Documentation
      • Medicines Act
      • EU Legislation
    • Home
  • Consultation

    • EU & Medicines Authority Consultations
      • EU & Medicines Authority Consultations
    • Home
  • News & Events

    • News
      • Press Releases
      • Circulars
      • Other News
      • Past News
    • Events
      • Latest Events
      • Past Events
    • Home
  • Online Services

    • Online Services
      • Eudrapharm
      • EU Common Submission Portal
      • Medicines Authority Notifications
      • Servizz.gov.mt
      • Online Applications (E-Forms)
    • Home
  • Contact and Connect

    • On Line Forms
      • Enquiries and Feedback
      • Complaints
      • Complaints related to Advertising of Medicinal Products
      • Report Product Defect
      • Report a Side Effect - Adverse Drug Reaction (ADR)
    • Connect and Share
      • Engage with us on Facebook
      • Follow us on LinkedIn
      • Follow us on Twitter
      • Connect with us on Google
      • Watch our videos on YouTube
    • Find Us
      • Contact Details
    • Home
  • Search for Malta Medicine
    Search »
    Search »
    Advanced Search »
  • Patient/Consumer
  • Industry
  • Healthcare Professional
  • Safety Information
  • Reporting Adverse Drug Reactions
  • Eudravigilance
  • Periodic Safety Update Reports
  • Safety Recalls

Activities

  • Registration of Medicinal Products
  • Pharmaceutical Activities and Inspections
  • Scientific Advice
  • Recalls and Rapid Alerts
  • Changes to prescription status
  • Safety Recalls
  • BREXIT - Regulatory considerations
  • Advanced Scientific Initiatives
  • Advertising
  • Borderline Products
  • Linguistic Checks
  • Safety
  • Clinical Trials
  • Enforcement and Market Surveillance

Safety Recalls

  • Home
  • >
  • Activities
  • >
  • Safety
  • >
  • Safety Recalls

Safety Recalls

In order to protect public health, it may become necessary to recall stock of medicinal products for human use due to pharmacovigilance/safety issues. Recalls due to combined safety and quality issues are also possible.

The recall of stock from the marketplace can apply to all authorised medicinal products (i.e. all marketing authorisations, authorisations in line with 126a, centrally authorised products, parallel imports, unlicensed medicinal products (article 20) and medicines which are available in Malta through a named patient basis or compassionate use programmes).

Once a recall is confirmed, the Post Licensing Directorate at the Medicines Authority is responsible for co-ordinating all aspects of pharmacovigilance/safety related recalls in Malta.

The basis for the recall of stock due to safety or pharmacovigilance reasons can be due to a Community Decision (as published in the Official Journal of the European Union), or a decision taken by a marketing authorisation holder to withdraw a marketing authorisation.

For Marketing Authorisation Holder

When a recall is confirmed, Marketing Authorisation Holders should inform the Medicines Authority about its co-ordinated plan to carry out the recall. The submission package could contain as applicable:

  1. Direct Healthcare Professional Communication (DHPC) and Action Plan
  2. Details about stopping the supply to wholesale dealers or pharmacies and the date of implementation
  3. Dissemination letters both to Pharmacies and wholesale dealers

The submission package can be sent electronically to postlicensing.medicinesauthority@gov.mt. The Medicines Authority will then review and approve the materials and upload any DHPC/Safety Circulars/Letters as applicable.

 

After the recall has been carried out a Reconciliation Report should be sent to the Inspectorate and Enforcement Directorate at Medicines Authority.

Enquiries and Further Information

For further information consult the Guidance Notes for Pharmaceutical Companies on Pharmacovigilance Obligations & Adverse Drug Reaction (ADR) Reporting Requirements for Medicinal Products for Human Use.

Enquiries can be made by mail, email, fax or telephone:

By Mail: 

Malta Medicines Authority

 

Sir Temi Żammit Buildings

 

Malta Life Sciences Park

 

San Ġwann SĠN 3000

By Phone:   

00356 23439000

By Fax:

00356 23439161

By Email:

postlicensing.medicinesauthority@gov.mt

Feedback

The Malta Medicines Authority thanks you for the time taken to visit our website. We kindly invite your anonymous feedback on your experience with this webpage. Feedback may be given through our online form.

Back to Top
  • Facebook
  • You Tube
  • Twitter
  • LinkedIn
  • Google Plus
  • Marker

Medicines Authority
Sir Temi Żammit Buildings,
Malta Life Sciences Park,
San Ġwann SĠN 3000
Malta

E-mail: info.medicinesauthority@gov.mt

Telephone: 356 2343 9000 (from 7:30 to 15:45)

Helpline: 356 2343 9111 (from 9:00 to 12:00)

Fax: 356 2343 9161

  • gov mt logo
  • hma logo
  • picis logo
  • MCCAA Logo
  • NCPE Logo
Malta Medicine Authority © Copyright 2019
  • Accessability
  • Disclaimer
  • Privacy Policy
  • Freedom of Information
  • Copyright
  • Contact and Connect